乙型肝炎患者抗结核药物相关性肝损害的产生及干预  

The Incidence of Antituberculosis Drug-related Hepatotoxicity in Patients with Hepatitis B and Intervention Study

作　　者：李盼盼[1] 周伏喜[1] 

机构地区：[1]中南大学湘雅二医院消化内科,长沙410011

出　　处：《医学综述》2014年第6期1054-1056,共3页Medical Recapitulate

摘　　要：近年来,结核发病率在我国呈上升趋势,异烟肼、利福平、吡嗪酰胺等一线抗结核药物最常见、最严重的不良反应之一是肝损害,在合并乙型肝炎病毒(HBV)感染的患者,其肝损害的发生更加突出,往往导致患者治疗中断。该文就抗结核药所致肝损害机制、HBV感染对抗结核药物致肝损害的影响及可行的干预措施作一综述,以期为合并HBV感染的结核患者的临床治疗提供参考。In recent years, the incidence of tuberculosis in China has showed an increasing tendency. Hepatotoxicity is one of the most common and serious adverse reactions of the first-line antitubereulosis drugs, such as isonieotinylhydrazide, rifampin and pyrazinamide, it＇s more visible in the patients with hepatitis B virus（HBV） ,which always leads to the interrupted treatment. Here is to make a review of the meehanism of antituberculosis drug-related hepatotoxicity,the influence of HBV infection on the hepatotoxicity and feasible intervention measures ,in order to offer references for clinical treatment HBV infected tuberculosis patients.

关 键 词：结核 乙型肝炎病毒 肝损害 

分 类 号：R45[医药卫生—治疗学] R511[医药卫生—临床医学]